Table 1.
Host range determination of the purified phage vB_PmiS_PM-CJR and its recombinant tail spike protein.
| Species | Source | Phage | Tail Spike | Reference |
|---|---|---|---|---|
| P. mirabilis BB2000 | Reference strain | +++ | +++ | [17] |
| P. mirabilis ATCC 51286 | Reference strain | +++ | – | – |
| P. mirabilis ATCC 35508 | Reference strain | ++ | – | – |
| P. mirabilis HI4320 ure− | Urease-negative mutant | – | – | [47] |
| P. mirabilis B2 | Clinical isolate | + | – | [48] |
| P. mirabilis B4 | Clinical isolate | ++ | – | [49] |
| P. mirabilis RB6 | Clinical isolate | – | – | [50] |
| P. mirabilis RB6A | Clinical isolate | – | – | – |
| P. mirabilis RB6B | Clinical isolate | – | – | – |
| P. mirabilis RS1 | Clinical isolate | – | – | [51] |
| P. mirabilis RS6 | Clinical isolate | – | – | [52] |
| P. mirabilis RS17 | Clinical isolate | – | – | [52] |
| P. mirabilis RS18 | Clinical isolate | – | – | [52] |
| P. mirabilis RS28 | Clinical isolate | + | – | [52] |
| P. mirabilis RS40 | Clinical isolate | ++ | – | [52] |
| P. mirabilis RS47 | Clinical isolate | ++ | – | [52] |
| P. mirabilis RS50a | Clinical isolate | + | – | [52] |
| P. penneri NCTC 12737 | Reference strain | + | – | – |
| P. vulgaris UM266 | Clinical isolate | + | – | – |
The level of effect of phage and the tail spike on different bacterial strains was qualitatively assessed and expressed using the following convention: strong effect (+++), moderate effect (++), weak effect (+), no detectable effect (–).